• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech ’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma

    FDA Grants Genentech ’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma

  2. SNP Trace Panel Proves to Be a High-Throughput, Cost-Effective SNP-Based Platform for Profiling Human Tissue and Cell Lines

    SNP Trace Panel Proves to Be a High-Throughput, Cost-Effective SNP-Based Platform for Profiling Human Tissue and Cell Lines

  3. Genentech ’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

    Genentech ’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

  4. FDA Grants Breakthrough Therapy Designation for Genentech ’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) in Non-Small Cell Lung Cancer

    FDA Grants Breakthrough Therapy Designation for Genentech ’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) in Non-Small Cell Lung Cancer

  5. Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

  6. Roche Gets FDA Priority Review for Cancer Treatment

    Roche Gets FDA Priority Review for Cancer Treatment

  7. Pfenex shares rise on collaboration deal with Hospira

    Pfenex shares rise on collaboration deal with Hospira

  8. Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics

    Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics

  9. New Leadership and Membership Changes for Federal Reserve Bank of San Francisco’s Economic Advisory Council

    New Leadership and Membership Changes for Federal Reserve Bank of San Francisco’s Economic Advisory Council

  10. ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results

    ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.